1[1]Denning DW. Echinocandins: a new class of antifungal[J]. Antimicrob Chemother, 2002, 49: 889-891
2[2]Letscher-Bra V, Herbfecht R. Caspofungin: the first representative of a new antifungal class[J]. J Antimicrob Chemother, 2003, 51: 513-521
3[3]Liu J, Balasubramanian MK.1,3-beta-Glucan synthase: a useful target for antifungal drugs[J]. Curr Drug Targets Infect Disord,2001,1:159-169
4[4]Arikan S, Lozano-Chiu M, Paetznick V,et al. In vitro susceptibility testing methods for caspofungin against aspergillus and fusarium isolates[J]. Antimicrob Agents Chemother, 2002; 45:327-330
5[5]Bowman JC, Abruzzo GK, Anderson JW,et al.Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate[J]. Antimicrob Agents Chemother,2001,45:3474-3481
6[6]González GM, Tijerina R,Najvar LK,et al.Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with Caspofungin in a mouse model[J]. Antimicrob Agents Chemother, 2001, 45: 1854-1859
7[7]Petraitiene R, Petraitis V, Groll AH,et al.antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia[J]. Antimicrob Agents Chemother, 2002, 46:12-23
8[8]Bachmann SP, Patterson TF, Lopez-Ribot JL.In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance[J]. J Clin Microbiol, 2002,40:2228-2230
9[9]Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice[J]. Antimicrob Agents Chemother, 2000,44:2310-2318
10[10]Ernst EJ, Klepser ME, Pfaller MA.Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans[J]. Antimicrob Agents Chemother, 2000,44:1108-1111
4Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin ,2003,19:263-271.
5Dupont B. Itraconazole therapy in aspergillosis:study in 49 patients.J Am Acad Dermatol,1990,23(3 Pt 2) :607-614.
6Quoix E, Gasser B, Apprill M, et al. Endobronchial aspergillosis associated with a carcinoid tumor. Rev Mal Respir, 1990,7:609-612.
7Sable CA,Nguyen BY,Chodakewitz JA,et aL Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis ,2002,4:25-30.
8Schwartz R E,Sesin D F,Joshua H,et al.Pneumocandins from Zalerion arboricola.I.Discovery and isolation[J].J Antibiot(Tokyo),1992,45(12):1853-1866.
9Schmatz D M,Abruzzo G,Powles M A,et al.Pneumocandins from Zalerion arboricola.Ⅳ.Biological evalution of natural and semisythetic pneumocandins for activity against Pneumocystis carinii and Candida species[J].JAntibiot(Tokyo),1992,45(12):1886-1891.
10Balkovec J M,Hughes D L,Masurekar P S,et al.Discovery and development of first in class antifungal caspofungin (CANCIDAS(R))--a case study[J].Nat ProdRep,2014,31(1):15-34.
